Kyungdong Pharmaceutical is showing strong performance following the news that it has successfully completed the domestic Phase 3 clinical trial of the improved combination drug for benign prostatic hyperplasia, KDF1905-2BO.
As of 10:34 AM on the 12th, Kyungdong Pharmaceutical is trading at 7,470 KRW, up 16.72% (1,070 KRW) from the previous trading day.
On the same day, Kyungdong Pharmaceutical announced that the domestic Phase 3 clinical trial of the improved combination drug for benign prostatic hyperplasia, ‘KDF1905-2BO,’ confirmed improvement in lower urinary tract symptoms.
KDF1905-2BO is a combination drug that combines tamsulosin (KDF1905-R1), a representative alpha-blocker for benign prostatic hyperplasia, and mirabegron (KDF1905-R2), an ingredient for treating overactive bladder. Tamsulosin and mirabegron are representative drugs with a high prescription rate in the urological field.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
